• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蛋白酶体在癌症中对蛋白质降解的调控

Regulation of Protein Degradation by Proteasomes in Cancer.

作者信息

Jang Ho Hee

机构信息

Department of Biochemistry, College of Medicine, Gachon University, Incheon, Korea.

出版信息

J Cancer Prev. 2018 Dec;23(4):153-161. doi: 10.15430/JCP.2018.23.4.153. Epub 2018 Dec 30.

DOI:10.15430/JCP.2018.23.4.153
PMID:30671397
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6330989/
Abstract

Imbalance of protein homeostasis (proteostasis) is known to cause cellular malfunction, cell death, and diseases. Elaborate regulation of protein synthesis and degradation is one of the important processes in maintaining normal cellular functions. Protein degradation pathways in eukaryotes are largely divided into proteasome-mediated degradation and lysosome-mediated degradation. Proteasome is a multisubunit complex that selectively degrades 80% to 90% of cellular proteins. Proteasome-mediated degradation can be divided into 26S proteasome (20S proteasome + 19S regulatory particle) and free 20S proteasome degradation. In 1980, it was discovered that during ubiquitination process, wherein ubiquitin binds to a substrate protein in an ATP-dependent manner, ubiquitin acts as a degrading signal to degrade the substrate protein via proteasome. Conversely, 20S proteasome degrades the substrate protein without using ATP or ubiquitin because it recognizes the oxidized and structurally modified hydrophobic patch of the substrate protein. To date, most studies have focused on protein degradation via 26S proteasome. This review describes the 26S/20S proteasomal pathway of protein degradation and discusses the potential of proteasome as therapeutic targets for cancer treatment as well as against diseases caused by abnormalities in the proteolytic system.

摘要

蛋白质稳态(蛋白质平衡)失衡会导致细胞功能异常、细胞死亡和疾病。对蛋白质合成和降解进行精细调控是维持正常细胞功能的重要过程之一。真核生物中的蛋白质降解途径主要分为蛋白酶体介导的降解和溶酶体介导的降解。蛋白酶体是一种多亚基复合物,可选择性地降解细胞内80%至90%的蛋白质。蛋白酶体介导的降解可分为26S蛋白酶体(20S蛋白酶体+19S调节颗粒)降解和游离20S蛋白酶体降解。1980年发现,在泛素化过程中,泛素以ATP依赖的方式与底物蛋白结合,泛素作为降解信号,通过蛋白酶体降解底物蛋白。相反,20S蛋白酶体不使用ATP或泛素就能降解底物蛋白,因为它能识别底物蛋白氧化和结构修饰后的疏水区域。迄今为止,大多数研究都集中在通过26S蛋白酶体进行的蛋白质降解上。本文综述了蛋白质降解的26S/20S蛋白酶体途径,并讨论了蛋白酶体作为癌症治疗以及抗蛋白水解系统异常所致疾病治疗靶点的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7752/6330989/248d5c65d3a3/jcp-23-153f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7752/6330989/ec9c40223383/jcp-23-153f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7752/6330989/66236b650103/jcp-23-153f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7752/6330989/248d5c65d3a3/jcp-23-153f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7752/6330989/ec9c40223383/jcp-23-153f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7752/6330989/66236b650103/jcp-23-153f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7752/6330989/248d5c65d3a3/jcp-23-153f3.jpg

相似文献

1
Regulation of Protein Degradation by Proteasomes in Cancer.蛋白酶体在癌症中对蛋白质降解的调控
J Cancer Prev. 2018 Dec;23(4):153-161. doi: 10.15430/JCP.2018.23.4.153. Epub 2018 Dec 30.
2
Proteasomes of the yeast S. cerevisiae: genes, structure and functions.酿酒酵母的蛋白酶体:基因、结构与功能
Mol Biol Rep. 1995;21(1):3-10. doi: 10.1007/BF00990964.
3
[Ubiquitin-independent protein degradation in proteasomes].蛋白酶体中不依赖泛素的蛋白质降解
Biomed Khim. 2018 Mar;64(2):134-148. doi: 10.18097/PBMC20186402134.
4
Chaperone activities of the 26S and 20S proteasome.26S和20S蛋白酶体的伴侣活性。
Curr Protein Pept Sci. 2005 Apr;6(2):197-203. doi: 10.2174/1389203053545453.
5
Degradation of oxidized proteins by the proteasome: Distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways.蛋白酶体对氧化蛋白质的降解:区分20S、26S和免疫蛋白酶体的蛋白水解途径。
Mol Aspects Med. 2016 Aug;50:41-55. doi: 10.1016/j.mam.2016.05.001. Epub 2016 May 4.
6
Comparative resistance of the 20S and 26S proteasome to oxidative stress.20S和26S蛋白酶体对氧化应激的抗性比较
Biochem J. 1998 Nov 1;335 ( Pt 3)(Pt 3):637-42. doi: 10.1042/bj3350637.
7
Redox regulation of the proteasome via S-glutathionylation.通过 S-谷胱甘肽化对蛋白酶体进行氧化还原调节。
Redox Biol. 2013 Dec 14;2:44-51. doi: 10.1016/j.redox.2013.12.003.
8
Proteasomes: Isolation and Activity Assays.蛋白酶体:分离与活性测定。
Curr Protoc. 2023 Apr;3(4):e717. doi: 10.1002/cpz1.717.
9
Degradation of oxidized proteins by the 20S proteasome.20S蛋白酶体对氧化蛋白质的降解作用。
Biochimie. 2001 Mar-Apr;83(3-4):301-10. doi: 10.1016/s0300-9084(01)01250-0.
10
Measurement of the Multiple Activities of 26S Proteasomes.26S蛋白酶体多种活性的测定
Methods Mol Biol. 2018;1844:289-308. doi: 10.1007/978-1-4939-8706-1_19.

引用本文的文献

1
Not Just PA28γ: What We Know About the Role of PA28αβ in Carcinogenesis.不仅仅是PA28γ:我们对PA28αβ在致癌作用中的作用的了解。
Biomolecules. 2025 Jun 16;15(6):880. doi: 10.3390/biom15060880.
2
The gold complex auranofin sensitizes platinum resistant epithelial ovarian cancer cells to cisplatin.金络合物金诺芬可使铂耐药的上皮性卵巢癌细胞对顺铂敏感。
Biochem Biophys Rep. 2025 Mar 29;42:101996. doi: 10.1016/j.bbrep.2025.101996. eCollection 2025 Jun.
3
CagA and Cag type IV secretion system activity have key roles in triggering gastric transcriptional and proteomic alterations.

本文引用的文献

1
Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.依沙佐米的临床药理学:首个口服蛋白酶体抑制剂。
Clin Pharmacokinet. 2019 Apr;58(4):431-449. doi: 10.1007/s40262-018-0702-1.
2
Regulation of proteasome assembly and activity in health and disease.蛋白酶体组装和活性的调控在健康和疾病中的作用。
Nat Rev Mol Cell Biol. 2018 Nov;19(11):697-712. doi: 10.1038/s41580-018-0040-z.
3
Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.卡非佐米相关心血管不良事件:系统评价和荟萃分析。
细胞毒素相关基因A(CagA)和CagⅣ型分泌系统活性在引发胃部转录和蛋白质组改变中起关键作用。
Infect Immun. 2025 Apr 8;93(4):e0059524. doi: 10.1128/iai.00595-24. Epub 2025 Mar 6.
4
Immunization with recombinant HPV16-E7d in fusion with Flagellin as a cancer vaccine: Effect of antigen-adjuvant orientation on the immune response pattern.用与鞭毛蛋白融合的重组HPV16-E7d作为癌症疫苗进行免疫接种:抗原-佐剂方向对免疫反应模式的影响。
Immunol Res. 2025 Feb 13;73(1):50. doi: 10.1007/s12026-025-09598-6.
5
Biomarker Landscape in RASopathies.RASopathy 相关生物标志物全景。
Int J Mol Sci. 2024 Aug 6;25(16):8563. doi: 10.3390/ijms25168563.
6
Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers.多组学分析鉴定硼替佐米在肾脏癌、神经系统癌和血液系统癌治疗中的再利用
Sci Rep. 2024 Aug 10;14(1):18576. doi: 10.1038/s41598-024-62339-x.
7
Global protein turnover quantification in Escherichia coli reveals cytoplasmic recycling under nitrogen limitation.在大肠杆菌中定量测定全球蛋白质周转率揭示了氮限制下的细胞质再循环。
Nat Commun. 2024 Jul 13;15(1):5890. doi: 10.1038/s41467-024-49920-8.
8
Plasticity of the proteasome-targeting signal Fat10 enhances substrate degradation.蛋白酶体靶向信号 Fat10 的可塑性增强了底物降解。
Elife. 2024 Jul 10;13:e91122. doi: 10.7554/eLife.91122.
9
Chemical Proteomics Reveals that the Anticancer Drug Everolimus Affects the Ubiquitin-Proteasome System.化学蛋白质组学揭示抗癌药物依维莫司影响泛素-蛋白酶体系统。
ACS Pharmacol Transl Sci. 2024 Feb 7;7(3):787-796. doi: 10.1021/acsptsci.3c00316. eCollection 2024 Mar 8.
10
PSMD1 as a prognostic marker and potential target in oropharyngeal cancer.PSMD1 作为口咽癌的预后标志物和潜在靶点。
BMC Cancer. 2023 Dec 16;23(1):1242. doi: 10.1186/s12885-023-11689-2.
JAMA Oncol. 2018 Mar 8;4(3):e174519. doi: 10.1001/jamaoncol.2017.4519.
4
The proteasome-interacting Ecm29 protein disassembles the 26S proteasome in response to oxidative stress.蛋白酶体相互作用蛋白Ecm29在氧化应激反应中会拆解26S蛋白酶体。
J Biol Chem. 2017 Sep 29;292(39):16310-16320. doi: 10.1074/jbc.M117.803619. Epub 2017 Aug 15.
5
Smurf1 regulates lung cancer cell growth and migration through interaction with and ubiquitination of PIPKIγ.Smurf1 通过与 PIPKIγ 相互作用和泛素化来调节肺癌细胞的生长和迁移。
Oncogene. 2017 Oct 12;36(41):5668-5680. doi: 10.1038/onc.2017.166. Epub 2017 Jun 5.
6
The Logic of the 26S Proteasome.26S蛋白酶体的逻辑
Cell. 2017 May 18;169(5):792-806. doi: 10.1016/j.cell.2017.04.023.
7
Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.突变型p53蛋白与Hippo信号转导分子YAP和TAZ:人类癌症中的关键致癌节点
Int J Mol Sci. 2017 May 3;18(5):961. doi: 10.3390/ijms18050961.
8
Wnt signaling in triple-negative breast cancer.三阴性乳腺癌中的Wnt信号传导
Oncogenesis. 2017 Apr 3;6(4):e310. doi: 10.1038/oncsis.2017.14.
9
New insights into autophagosome-lysosome fusion.自噬体-溶酶体融合的新见解。
J Cell Sci. 2017 Apr 1;130(7):1209-1216. doi: 10.1242/jcs.196352. Epub 2017 Mar 16.
10
Degradation of oxidized proteins by the proteasome: Distinguishing between the 20S, 26S, and immunoproteasome proteolytic pathways.蛋白酶体对氧化蛋白质的降解:区分20S、26S和免疫蛋白酶体的蛋白水解途径。
Mol Aspects Med. 2016 Aug;50:41-55. doi: 10.1016/j.mam.2016.05.001. Epub 2016 May 4.